Abstract
The term neurodegenerative disease refers to the principal pathology associated with disorders such as amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease and Parkinson's disease, and it is presumed that neurodegeneration results in the clinical findings seen in patients with these diseases. Decades of pathological and physiological studies have focused on neuronal abnormalities in these disorders, but it is becoming increasingly evident that astrocytes are also important players in these and other neurological disorders. Our understanding of the normative biology of astrocytes has been aided by the development of animal models in which astrocyte-specific proteins and pathways have been manipulated, and mouse models of neurodegenerative diseases have also revealed astrocyte-specific pathologies that contribute to neurodegeneration. These models have led to the development of targeted therapies for pathways in which astrocytes participate, and this research should ultimately influence the clinical treatment of neurodegenerative disorders.
Key Points
-
Astrocytes perform critical roles in amino acid, nutrient and ion metabolism in the brain, coupling of neuronal activity and cerebral blood flow, and modulation of excitatory synaptic transmission
-
Transgenic and knockout mouse models of astrocyte-specific proteins have demonstrated that astrocytes play a role in both neuroprotection and neurodegeneration, particularly following an insult
-
Selective expression of mutant proteins associated with neurodegenerative diseases in astrocytes is sufficient to cause neuronal damage
-
Mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein is associated with the neurodegenerative disorder Alexander disease
-
Astrocytes might be particularly attractive—and underappreciated—targets for neurodegenerative disease therapeutics
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65: 1–105
Kofuji P and Newman EA (2004) Potassium buffering in the central nervous system. Neuroscience 129: 1045–1056
Hirase H (2005) A multi-photon window onto neuronal-glial-vascular communication. Trends Neurosci 28: 217–219
Takano T et al. (2006) Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 9: 260–267
Chaudhry FA et al. (1995) Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 15: 711–720
Lehre KP et al. (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J Neurosci 15: 1835–1853
Milton ID et al. (1997) Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Mol Brain Res 52: 17–31
Rothstein JD et al. (1994) Localization of neuronal and glial glutamate transporters. Neuron 13: 713–725
Rothstein JD et al. (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16: 675–686
Tanaka K et al. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699–1702
Bezzi P et al. (2001) CXCR4-activated astrocyte glutamate release via TNFα: amplification by microglia triggers neurotoxicity. Nat Neurosci 4: 702–710
Haydon PG (2001) Glia: listening and talking to the synapse. Nat Rev Neurosci 2: 185–193
Ye ZC et al. (2003) Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci 23: 3588–3596
Simard M and Nedergaard M (2004) The neurobiology of glia in the context of water and ion homeostasis. Neuroscience 129: 877–896
Pekny M (2001) Astrocytic intermediate filaments: lessons from GFAP and vimentin knock-out mice. Prog Brain Res 132: 23–30
Eng LF et al. (1998) Astrocytes cultured from transgenic mice carrying the added human glial fibrillary acidic protein gene contain Rosenthal fibers. J Neurosci Res 53: 353–360
Wilhelmsson U et al. (2004) Absence of glial fibrillary acidic protein and vimentin prevents hypertrophy of astrocytic processes and improves post-traumatic regeneration. J Neurosci 24: 5016–5021
Tanaka K et al. (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699–1702
Mitani A and Tanaka K (2003) Functional changes of glial glutamate transporter GLT-1 during ischemia: an in vivo study in the hippocampal CA1 of normal mice and mutant mice lacking GLT-1. J Neurosci 23: 7176–7182
Watanabe T et al. (1999) Amygdala-kindled and pentylenetetrazole-induced seizures in glutamate transporter GLAST-deficient mice. Brain Res 845: 92–96
Mallolas J et al. (2006) A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med 203: 711–717
Sofroniew MV (2005) Reactive astrocytes in neural repair and protection. Neuroscientist 11: 400–407
Dermietzel R et al. (1991) Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J Neurosci 11: 1421–1432
Reaume AG et al. (1995) Cardiac malformation in neonatal mice lacking connexin43. Science 267: 1831–1834
Siushansian R et al. (2001) Connexin43 null mutation increases infarct size after stroke. J Comp Neurol 440: 387–394
Patel SA and Maragakis NJ (2002) Amyotrophic lateral sclerosis: pathogenesis, differential diagnoses, and potential interventions. J Spinal Cord Med 25: 262–273
Bristol LA and Rothstein JD (1996) Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann Neurol 39: 676–679
Lin CL et al. (1998) Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 20: 589–602
Meyer T et al. (1999) The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals. J Neurol Sci 170: 45–50
Flowers JM et al. (2001) Intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis. Ann Neurol 49: 643–649
Gurney ME et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772–1775
Wong PC et al. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14: 1105–1116
Bruijn LI et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18: 327–338
Howland DS et al. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 99: 1604–1609
Guo H et al. (2003) Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 12: 2519–2532
Clement AM et al. (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113–117
Miller TM et al. (2005) Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 57: 773–776
Ralph GS et al. (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11: 429–433
Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741–766
Wisniewski HM and Wegiel J (1991) Spatial relationships between astrocytes and classical plaque components. Neurobiol Aging 12: 593–600
DeWitt DA et al. (1998) Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 149: 329–340
Nagele RG et al. (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25: 663–674
Haughey NJ and Mattson MP (2003) Alzheimer's amyloid beta-peptide enhances ATP/gap junction-mediated calcium-wave propagation in astrocytes. Neuromolecular Med 3: 173–180
Johnston JM et al. (2006) Calcium oscillations in type-1 astrocytes, the effect of a presenilin 1 (PS1) mutation. Neurosci Lett 395: 159–164
Feany MB and Dickson DW (1995) Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 146: 1388–1396
Komori T (1999) Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 9: 663–679
Forman MS et al. (2005) Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration. J Neurosci 25: 3539–3550
Dabir DV et al. (2006) Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J Neurosci 26: 644–654
Hersch SM et al. (2004) In Neurologic Principles and Practice, 503–526 (Ed Koller W) New York: McGraw-Hill
Singhrao SK et al. (1998) Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp Neurol 150: 213–222
Arzberger T et al. (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease—an in situ hybridization study. J Neuropathol Exp Neurol 56: 440–454
Rothstein JD et al. (1992) Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326: 1464–1468
Vis JC et al. (1998) Connexin expression in Huntington's diseased human brain. Cell Biol Int 22: 837–847
Lievens JC et al. (2001) Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol Dis 8: 807–821
Behrens PF et al. (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125: 1908–1922
Shin JY et al. (2005) Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 171: 1001–1012
Nutt JG and Wooten GF (2005) Clinical practice: diagnosis and initial management of Parkinson's disease. N Engl J Med 353: 1021–1027
Forno LS et al. (1992) Astrocytes and Parkinson's disease. Prog Brain Res 94: 429–436
Damier P et al. (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52: 1–6
Wakabayashi K et al. (2000) NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol (Berl) 99: 14–20
Teismann P and Schulz JB (2004) Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318: 149–161
Saura J et al. (2003) Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J Neurochem 85: 651–661
Heales SJ et al. (2004) Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem Res 29: 513–519
Maragakis NJ and Rothstein JD (2004) Glutamate transporters: animal models to neurologic disease. Neurobiol Dis 15: 461–473
Brenner M et al. (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27: 117–120
Li R et al. (2005) Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol 57: 310–326
Rothstein JD et al. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73–77
Watanabe M et al. (2001) Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933–941
Author information
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Maragakis, N., Rothstein, J. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Rev Neurol 2, 679–689 (2006). https://doi.org/10.1038/ncpneuro0355
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0355
This article is cited by
-
Neuropathogenesis-on-chips for neurodegenerative diseases
Nature Communications (2024)
-
Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases
Archives of Toxicology (2024)
-
LRP10 and α-synuclein transmission in Lewy body diseases
Cellular and Molecular Life Sciences (2024)
-
Astrocytes evoke a robust IRF7-independent type I interferon response upon neurotropic viral infection
Journal of Neuroinflammation (2023)
-
Methylmalonic Acid Impairs Cell Respiration and Glutamate Uptake in C6 Rat Glioma Cells: Implications for Methylmalonic Acidemia
Cellular and Molecular Neurobiology (2023)